Chugai To Focus On Tarceva Post-market Surveillance
This article was originally published in PharmAsia News
Executive Summary
After obtaining an additional indication of pancreatic cancer for anti-cancer agent Tarceva (erlotinib), Chugai Pharmaceutical said the company will implement an all-case postmarket surveillance system to ensure proper drug use